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Physiologic changes in pregnancy induce profound alterations to the pharmacokinetic
properties ofmanymedications.These changes affect distribution, absorption, metabolism,
and excretion of drugs, and thus may impact their pharmacodynamic properties during
pregnancy. Pregnant women undergo several adaptations in many organ systems. Some
adaptations are secondary to hormonal changes in pregnancy, while others occur to
support the gravid woman and her developing fetus. Some of the changes in maternal
physiology during pregnancy include, for example, increased maternal fat and total body
water, decreased plasma protein concentrations, especially albumin, increased maternal
blood volume, cardiac output, and blood ﬂow to the kidneys and uteroplacental unit,
and decreased blood pressure. The maternal blood volume expansion occurs at a larger
proportion than the increase in red blood cell mass, which results in physiologic anemia
and hemodilution. Other physiologic changes include increased tidal volume, partially
compensated respiratory alkalosis, delayed gastric emptying and gastrointestinal motility,
and altered activity of hepatic drugmetabolizing enzymes. Understating these changes and
their profound impact on the pharmacokinetic properties of drugs in pregnancy is essential
to optimize maternal and fetal health.
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INTRODUCTION
Prescription and over-the-counter medications use is common
in pregnancy, with the average pregnant patient in the US and
Canada using more than two drugs during the course of their
pregnancy (Mitchell et al., 2001). One reason for this is that some
women enter into pregnancy with pre-existing medical condi-
tions, such as diabetes, hypertension, asthma, and others, that
require pharmacotherapy; and for many others, gestational dis-
orders (hyperemesis gravidarum, gestational diabetes, preterm
labor) complicate women’s pregnancies and require treatment.
Moreover, virtually the majority of organ systems are affected
by substantial anatomic and physiologic changes during preg-
nancy, with many of these changes beginning in early gestation.
Many of these alterations signiﬁcantly affect the pharmacoki-
netic (absorption, distribution, metabolism, and elimination)
and pharmacodynamic properties of different therapeutic agents
(Pacheco et al., 2013). Therefore, it becomes essential for clinicians
and pharmacologists to understand these pregnancy adaptations,
in order to optimize pharmacotherapy in pregnancy, and limit
maternal morbidity because of over- or under-treating pregnant
women. The purpose of this review is to summarize some of the
physiologic changes during pregnancy that may affect medication
pharmacokinetics.
CARDIOVASCULAR SYSTEM
Pregnancy is associated with signiﬁcant anatomic and physio-
logic remodeling of the cardiovascular system. Ventricular wall
mass, myocardial contractility, and cardiac compliance increase
(Rubler et al., 1977). Both heart rate and stroke volume increase
in pregnancy leading to a 30–50% increase in maternal cardiac
output (CO) from 4 to 6 l/min (Figure 1; Clark et al., 1989).
These changes occur primarily early in pregnancy, and 75% of
the increase will occur by the end of the ﬁrst trimester (Cape-
less and Clapp, 1991; Pacheco et al., 2013). CO plateaus between
28 and 32 weeks gestation, and then does not change signif-
icantly until delivery (Robson et al., 1989). During the third
trimester, the increase in heart rate becomes primarily respon-
sible for maintaining the increase in CO (Pacheco et al., 2013).
This increase in CO is preferential in which uterine blood ﬂow
increases 10-fold (17% of total CO compared with 2% prepreg-
nancy) and renal blood ﬂow increases 50%; whereas there is
minimal alterations to liver and brain blood ﬂow (Frederiksen,
2001). In addition, when compared with nulliparous women,
multiparous women have higher CO (5.6 vs. 5.2 l/min), stroke
volume (73.5 vs. 70.5 mL), and higher heart rate (Turan et al.,
2008). During labor and immediately after delivery, CO increases
as a result of increased blood volume (300–500 mL) with each
uterine contraction, and then secondarily to “auto-transfusion”
or the redirection of blood from the uteroplacental unit back to
the maternal circulation after delivery (Pacheco et al., 2013). As
CO increases, pregnant women experience a signiﬁcant decrease
in both systemic and pulmonary vascular resistances (Clark et al.,
1989). Secondary to the vasodilatory effects of progesterone, nitric
oxide and prostaglandins, systemic vascular resistances, and blood
pressure decrease early in pregnancy, reaching their lowest point
at 20–24 weeks, and leading to physiologic hypotension. Fol-
lowing this decrease, vascular resistances and secondarily blood
pressure begin rising again, approaching the pre-pregnancy val-
ues by term (Clark et al., 1989; Seely and Ecker, 2011). This is
especially important in patients with preexisting hypertension
and who are on antihypertensive drugs (Pacheco et al., 2013;
Table 1).
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FIGURE 1 | Alterations in heart rate (HR, beats/min) and stroke volume
(SV, mL) during pregnancy. The X-axis represents gestational ages in
weeks. NP represents the non-pregnant state (Figure adapted from Robson
et al., 1989).
Starting at 6-8 weeks of gestation and peaking at 32 weeks,
maternal blood volume increases by 40–50% above non-pregnant
volumes (Hytten and Paintin, 1963). This, coupled with drop
in serum albumin concentration, leads to decreased serum col-
loid osmotic pressure and hemodilutional anemia. Because of the
increased compliance of the right and left ventricles in pregnancy,
the pulmonary occlusion and central venous pressures remain
ﬁxed (Bader et al., 1955). While exact origin of the increased
blood volume is not fully understood, the mechanism may be
through nitric oxide mediated vasodilatation and increased argi-
nine vasopressin production and mineralocorticoid activity, with
water and sodium retention, leading to hypervolemia (Winkel
et al., 1980). The pregnancy induced hypervolemia is thought to
provide survival advantage to the pregnant women, protecting her
from hemodynamic instability with the blood loss at the time of
delivery (Carbillon et al., 2000; Pacheco et al., 2013).
The increase in total body water, blood volume, and capillary
hydrostatic pressure increase signiﬁcantly the volume of distri-
bution of hydrophilic substrates. Clinically, a larger volume of
distribution could necessitate a higher initial and maintenance
dose of hydrophilic drugs to obtain therapeutic plasma concen-
trations. Additionally, because of the decrease in serum albumin
concentrations and other drug-binding proteins during preg-
nancy; drugs, that are highly protein bound, may display higher
free levels due to decreased protein binding availability, and thus
higher bioactivity. For example, if a drug is highly (99%) bound to
albumin in non-pregnant patients, a small drop in protein binding
to 98% in pregnancy translates into doubling of the drug’s active
fraction in pregnancy. Digoxin, midazolam, and phenytoin are
examples of medications primarily bound to albumin (Pacheco
et al., 2013).
RESPIRATORY SYSTEM
Due to the increase in estrogen concentrations in pregnancy,
the respiratory system undergoes anatomic changes leading to
increased vascularity and edema of the upper respiratory mucosa
(Taylor, 1961). This may explain the increased prevalence of rhini-
tis and epistaxis during pregnancy. Although it is a theoretical risk
and no studies have shown increased toxicity, inhaled medica-
tions, such as steroids used to treat asthma, may be more readily
absorbed by pregnant patients (Pacheco et al., 2013).
Pregnancy is associated with increase in tidal volume by 30–
50%, which starts early in the ﬁrst trimester. While the respiratory
rate is not different compared to non-pregnant state, minute
ventilation (the product of respiratory rate and tidal volume) is
signiﬁcantly increased, similarly, by 30–50%. These changes are
mainly driven by the increase in progesterone concentrations in
pregnancy (Elkus and Popovich, 1992; McAuliffe et al., 2002). In
addition, the diaphragm is pushed 4–5 cm upward due to the
increased intra-abdominal pressure from the enlarging uterus and
ﬂuid third spacing. This leads to bibasilar alveolar collapse, basilar
atelectasis, and decreased in both functional residual capacity and
total lung capacity decrease by 10–20% (Baldwin et al., 1977; Tsai
and De Leeuw, 1982). The decrease in functional residual capacity
may predispose pregnant patient to hypoxemia during induc-
tion of general anesthesia. The vital capacity remains unchanged,
as the decreased expiratory reserve volumes are accompanied
with increased inspiratory reserve volumes (Baldwin et al., 1977;
Pacheco et al., 2013).
When evaluating blood gases in pregnancy, it is important to
note that the arterial partial pressure of oxygen (PaO2) is normally
increased to 101–105 mmHg and that of carbon dioxide (PaCO2)
Table 1 | Summary of cardiovascular changes during pregnancy.
Variable Change
Cardiac output Increased by 30–50%
Stroke volume Increases to a maximum of 85 mL at 20 weeks of gestation
Heart rate Increased (approaches 90–100 beats/minute at rest during the third trimester)
Systemic vascular resistances Decrease 21% (nadir at 20–24 weeks)
Pulmonary vascular resistances Decrease by 34%
Pulmonary capillary wedge pressure No signiﬁcant change
Colloid osmotic pressure Decreased by 14%
Hemoglobin concentration Decreased
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decreased to 28–31 mmHg. These changes are mainly driven by
the increase in minute ventilation described above. The drop of
PaCO2 in the maternal circulation creates a gradient between the
PaCO2 of themother and fetus, which allows CO2 to diffuse freely
from the fetus, through the placenta, and into the mother, where
it can be eliminated through the maternal lungs (Pacheco et al.,
2013). In addition,maternal arterial blood pH is slightly increased
to 7.4–7.45 and consistent with mild respiratory alkalosis. This
alkalosis is partially corrected by increased renal excretion of bicar-
bonate, leading to reduced serumbicarbonate level between 18 and
21 meq/L, and reduced buffering capacity (Elkus and Popovich,
1992; Pacheco et al., 2013). This partially compensated respira-
tory alkalosis slightly shifts the oxy-hemoglobin dissociation curve
rightward, thereby favoring dissociation of oxygen and facilitat-
ing its transfer across the placenta, but it also may affect protein
binding of some drugs (Tsai and De Leeuw, 1982).
RENAL SYSTEM
The effects of progesterone and relaxin on smoothmuscles are also
seen in the urinary system leading to dilation of the urinary collect-
ing system with consequent urinary stasis, predisposing pregnant
women to urinary tract infections (Rasmussen and Nielse, 1988).
This is more common on the right side secondary to dextrorota-
tion of the pregnant uterus, and the right ovarian vein that crosses
over the right ureter.
Both renal blood ﬂow and glomerular ﬁltration rate (GFR)
increase by 50%, as early as 14 weeks of pregnancy (Davi-
son and Dunlop, 1984). The mechanisms behind the increase
in GFR are probably secondary to vasodilation of afferent and
efferent arterioles. The increase in GFR leads to decreased
serum creatinine concentrations, so that when serum creati-
nine concentration is above 0.8 mg/dL during pregnancy, it may
indicate an underlying renal dysfunction (Pacheco et al., 2013)
The increase in renal clearance can have signiﬁcant increase
(20–65%) in the elimination rates of renally cleared medica-
tions leading to shorter half-lives. For example, the clearance
of lithium, which used to treat bipolar disorder, is doubled
during the third trimester of pregnancy compared with the non-
pregnant state, leading to sub-therapeutic drug concentrations
(Schou et al., 1973; Pacheco et al., 2013). Other drugs that are
eliminated by the kidneys include ampicillin, cefuroxime, cephara-
dine, cefazolin, piperacillin, atenolol, digoxin, and many others
(Anderson, 2005).
The kidneys are also mainly involved in water and sodium
osmoregulation. Vasodilatory prostaglandins, atrial natriuretic
factor, and progesterone favor natriuresis; whereas aldosterone
and estrogen favor sodium retention (Barron and Lindheimer,
1984). Although elevated GFR leads to additional sodium wast-
ing, the higher level of aldosterone, which reabsorbs sodium in
the distal nephron, offsets this wasting (Barron and Lindheimer,
1984). The resulting outcome is one of signiﬁcant water and
sodium retention during pregnancy, leading to cumulative reten-
tion of almost a gram of sodium, and a hefty increase in total
body water by 6–8 l including up to 1.5 l in plasma volume and
3.5 l in the fetus, placenta, and amniotic ﬂuid. This “dilutional
effect” leads to mildly reduced serum sodium (concentration of
135–138 meq/L compared with 135–145 meq/L in non-pregnant
women) as well as serum osmolarity (normal value in pregnancy
∼280mOsm/L comparedwith 286–289mOsm/L innon-pregnant
women; Schou et al., 1973). Another consequence of this volume
expansion is reduced in peak serum concentrations (Cmax) of
many hydrophilic drugs, particularly if the drug has a relatively
small volume of distribution.
GASTROINTESTINAL SYSTEM
In pregnancy, the rise in progesterone leads to delayed gastric
emptying and prolonged small bowel transit time, by ∼30–50%.
Increased gastric pressure, caused by delayed emptying as well as
compression from the gravid uterus, along with reduced resting
muscle tone of the lower esophageal sphincter, sets the stage for
gastro-esophageal reﬂux during pregnancy (Cappell and Garcia,
1998). In addition, these changes alter bioavailability parame-
ters like Cmax and time to maximum concentration (Tmax) of
orally administered medications (Parry et al., 1970). The decrease
in Cmax and increase in Tmax are especially concerning for med-
ications that are taken as a single dose, because a rapid onset
of action is typically desired for these medications (Dawes and
Chowienczyk, 2001).
Drug absorption is also decreased by nausea and vomiting early
in pregnancy. This results in lower plasma drug concentrations.
For this reason, patients with nausea and vomiting of pregnancy
(NVP) are routinely advised to take their medications when nau-
sea isminimal. Moreover, the increased prevalence of constipation
and the use of opiate medications to ease pain during labor slow
gastrointestinal motility, and delay small intestine drug absorp-
tion. This may lead to elevated plasma drug levels postpartum
(Clements et al., 1978). The increase in gastric pH may increase
ionization of weak acids, reducing their absorption. In addition,
drug-drug interaction becomes important as antacids and iron
may chelate co-administered drugs, which further decreases their
already reduced absorption (Carter et al., 1981).
The increase in estrogen in pregnancy leads to increase in
serum concentrations of cholesterol, ceruloplasmin, thyroid bind-
ing globulin, and cortisol binding globulin, ﬁbrinogen and many
other clotting factors (Lockitch, 1997). Serum alkaline phos-
phatase is elevated during pregnancy as it is also produced by
the placenta, and its levels in pregnant women may be two to four
times those of non-pregnant individuals; therefore limiting its
clinical utility when liver function or enzymes are assayed (Lock-
itch, 1997; Pacheco et al., 2013). The rest of liver function tests
such as serum transaminases (SGOT, SGPT), lactate dehydroge-
nase, bilirubin, and gamma-glutamyl transferase are not affected
(Lockitch, 1997).
Drugmetabolism is also altered in pregnancy in part secondary
to elevated sex hormones and changes in drug metabolizing
enzymes including those involved in phase I (reduction, oxi-
dation, or hydrolysis) or phase II (glucuronidation, acetylation,
methylation, and sulfation)metabolism (Evans andRelling, 1999).
Cytochrome P450 (CYP450) represents a family of oxidative
liver enzymes, and is a major route of drug metabolism for
many drugs. For example, CYP3A4 exhibits a broad substrate
speciﬁcity that includes nifedipine, carbamazepine, midazolam,
and the anti-retroviral drugs saquinavir, indinavir, lopinavir,
and ritonavir as well as many other drugs (Evans and Relling,
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1999; Schwartz, 2003; Mattison and Zajicek, 2006). Because
CYP3A4’s abundance and activity increase in pregnancy, the
clearance of its substrates is also increased, requiring dose adjust-
ment (Little, 1999). Examples of changes in phase II metabolism
include increased activity of the conjugating enzyme uridine
5′-diphospho-glucuronosyltransferase (UGT) 1A4, which leads to
increased oral clearance of lamotrigine, one of its substrates (de
Haan et al., 2004; Pacheco et al., 2013).
HEMATOLOGIC AND COAGULATION SYSTEMS
White (WBC) and red blood cell (RBC) counts increase dur-
ing pregnancy. The ﬁrst is thought to be secondary to bone
marrow granulopoiesis; whereas the 30% increase in RBC mass
(250–450 mL) is mainly driven by the increase in erythropoi-
etin production. The higher WBC count can sometimes make
diagnosis of infection challenging; however normally the increase
in WBC is not associated with signiﬁcant increase in bands or
other immature WBC forms (Pacheco et al., 2013). Despite the
increase in RBC mass, and as previously described, plasma vol-
ume increases signiﬁcantly much higher (∼45%), which leads to
“physiologic anemia” of pregnancy. Anemia usually peaks early in
the third trimester (30–32 weeks) and may become clinically sig-
niﬁcant in patients already anemic (iron deﬁciency, thalassemia,
etc.) at entry to pregnancy (Pritchard, 1965; Peck andArias, 1979).
This physiologic hemodilution may provide survival advantage
to women during pregnancy and childbirth, since the less vis-
cous blood improves uterine and intervillous perfusion, while
the increased red cell mass, coupled with increased uterine blood
ﬂow, optimizes oxygen transport to the fetus, and at the same
time the blood lost during delivery will be more dilute (Koller,
1982; Letsky, 1995; Pacheco et al., 2013). The increase in RBC
mass is accompanied by increased in maternal demand of iron
by an additional 500 mg during pregnancy. This is coupled with
an additional 300 mg of iron that is transferred to the fetus and
200 mg that is required for normal daily iron losses, making the
total iron requirement in pregnancy around 1 g (Pacheco et al.,
2013).
Pregnancy is a hypercoagulable state secondary to blood stasis
as well as changes in the coagulation and ﬁbrinolytic pathway such
as increased plasma levels of clotting factors (VII,VIII,IX,X,XII),
ﬁbrinogen, and vonWillebrand factor. Fibrinogen increases start-
ing in the ﬁrst trimester and peaks during the third trimester in
anticipation of delivery. Prothrombin and factor V levels remain
the same during pregnancy. Whereas, protein S decreases in
pregnancy, protein C does not usually change and thus can be
assayed if needed in pregnancy. Free antigen levels of the pro-
tein S above 30% in the second trimester and 24% in the third
trimester are considered normal during pregnancy (Pacheco et al.,
2013). Anti-thrombin III levels do not change, however, plas-
minogen activator levels are decreased and those of plasminogen
activator inhibitor (PAI-1) levels increased by 2–3 fold, leading to
suppressed ﬁbrinolytic state in pregnancy. Platelet function and
routine coagulation screen panels remain normal. This hyper-
coagulable state may offer a survival advantage by minimizing
blood loss after delivery, but it also predisposes pregnant women
to higher risks for thromboembolism (Hehhgren, 1996; Pacheco
et al., 2013).
ENDOCRINE SYSTEM
Plasma iodide concentration decreases in pregnancy because of
fetal use and increase in maternal clearance of iodide. This predis-
poses the thyroid gland to increase in size and volume in almost
15% of women. In addition to anatomic changes, the thyroid
gland increases production of thyroid hormones during preg-
nancy. This is due to the up-regulation of thyroid binding globulin,
which is the major thyroid hormone binding protein, by almost
150% from a pre-pregnancy concentration of 15–16 mg/L to 30–
40 mg/L in mid-gestation. This massive increase is driven by the
hyper-estrogenic milieu in pregnancy and reduced hepatic clear-
ance. The net result is increase in total tetra-iodothyronin and
tri-iodothyronin hormones (TT4 and TT3) in pregnancy. Despite
the increase in total T4 andT3, the free forms of the hormones (fT4
and fT3) remain relatively stable or slightly decreased but remain
within normal values and these patients are clinically euthyroid
(Glinoer, 1997; Glinoer, 1999; Pacheco et al., 2013). The increased
thyroid hormones production takes place mostly in the ﬁrst half
of gestation, plateauing around 20 weeks until term. Clinically,
due to these changes, the use of total T4, total T3 and resin tri-
iodothyronine uptake is not recommended to monitor thyroid
hormone status in pregnancy as they will be increased (TT4, TT3)
and decreased (rT3U), respectively. For patients with hypothy-
roidism and who require levothyroxine replacement in pregnancy,
it is recommended that they increase their levothyroxine dose by
30% early in pregnancy, be monitored during pregnancy, and
to decrease the dose in the postpartum period (Alexander et al.,
2004).
Thyroid stimulating hormone (TSH) decreases during the ﬁrst
half of pregnancy due to negative feedback fromperipheral T3 and
T4 secondary to thyroid gland stimulation by human chorionic
gonadotropin (hCG). During the ﬁrst half of pregnancy, a normal
value of TSH is between 0.5–2.5 mIU/L (as compared to an upper
limit of normal value for TSH of 5 mIU/L in the non-pregnant
state). Other factors that affect thyroid hormones metabolism and
levels in pregnancy include: (1) the increase in maternal renal
iodine excretion (secondary to increase in GFR), (2) the higher
maternal metabolic demands and rate during pregnancy, (3) the
thyrotropic action of hCG which shares a similar α subunit with
the TSH receptor and has a weak thyroid stimulating activity, (4)
the increase in thyroid hormones transplacental transport to the
fetus early in pregnancy, and (5) the increase in activity of placental
type III 5-deiodinase (the enzymes that converts T4 to the inactive
reverse T3; Glinoer, 1997; Glinoer, 1999; Pacheco et al., 2013).
CONCLUSION
Profound physiologic and anatomic changes occur in virtually
every organ system during pregnancy. These have signiﬁcant
consequences on the pharmacokinetic and pharmacodynamic
properties of various medications when used by pregnant women.
Data are lacking on the implications of these changes on variety
of therapeutic agents, and future research is desperately needed.
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